Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study

• DOI: 10.26442/18151434.2023.3.202457
• Publication Date: 2023-12-10T19:55:06Z
• Authors: Vladimir I. Evdok...; Anatoly A. Bloshc...; Alexander E. Abol...; Alexey A. Vilensky; Michail S. Laskov
• Keywords: 03 medical and health sciences; 0302 clinical medicine

Aim. To evaluate the effectiveness of trastuzumab deruxtecan in real-world practice Russian Federation.
 Materials and methods. We performed a retrospective analysis clinical case series related to use (N=15) setting single center, University Headache Clinic (Dr. Laskov's Clinic), as part program for import an unapproved drug life-saving measure. The overall survival, progression-free objective response rate were assessed, individual cases efficacy presented.
 Results. Objective rates are comparable those shown large randomized trials. median follow-up was 67 days; 6-month survival 70.1% (95% confidence interval [CI] 49.4–99.6%), 52.1% CI 29.9–90.6%). There no significant complications associated with therapy; particular, events interstitial lung disease reported.
 Discussion. that However, at level cases, slightly lower noted initially frailer patients (ECOG score 3). Also, it should be study included who had opportunity purchase expensive and, therefore, social status different from general population, which could affect results this study.
 Conclusion. settings has demonstrated high good safety profile.